LEFF JONATHAN S 4

What Happened

• Jonathan S. Leff, a director of Larimar Therapeutics (LRMR), was granted a derivative award (options) covering 55,150 shares on May 19, 2026. The Form 4 reports the acquisition price as $0.00 and a total reported value of $0. This is a grant/award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-19; Grant type: award/options (A); Reported price: $0.00; Quantity: 55,150 shares (derivative).
• Vesting: options vest on the earlier of (a) May 19, 2027 or (b) the date of the company’s next annual meeting, subject to Leff’s continued board service (per footnote).
• Beneficial ownership note: Leff is a partner in Deerfield Management Company, L.P.; he disclaims personal beneficial ownership and holds the options for the benefit and at the direction of Deerfield (per footnote).
• Filing: Form 4 was filed 2026-05-20 for a 2026-05-19 transaction — appears promptly filed (no late-filing flag shown in the provided data).
• Shares owned after transaction: not specified in the provided filing extract.

Context

• This was a derivative grant (options) that vest over time rather than an immediate cash purchase or sale. Such awards are commonly used to align directors’ incentives with shareholders, but they do not represent an immediate cash transaction or share sale. The Reporting Person’s footnote clarifies the options are held for an institutional investor (Deerfield), not personally owned by Leff.